Download Files:
Products Details
Product Description
– Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor[1][2].
Web ID
– HY-50895G
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H24ClFN4O3
References
– [1]Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. |[2]Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28(1):50. |[3]Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2(3):e39.
CAS Number
– 184475-35-2
Molecular Weight
– 446.90
SMILES
– ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F
Clinical Information
– Phase 4
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Autophagy;EGFR
Pathway
– Apoptosis;Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
